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ABSTRACT 
 
 
The relationship of olfactory functioning and hormones is complex, and, for the most part, 
heterogenous. The present study aims to clarify and or define aspects of this relationship by 
examining how olfactory thresholds fluctuate in relation to changing hormone levels in two 
populations: menstruating and pregnant women. A longitudinal study was implemented to assess 
women at two different times. A total of 72 non-pregnant and 7 pregnant women participated in 
the first assessment, with a total of 62 non-pregnant and all 7 pregnant women returning for the 
second assessment. During each examination participants had blood drawn and were 
administered a threshold test. The Wheeler-University of Tennessee at Chattanooga odor 
threshold test (WUTC) allowed for the measurement of odorant sensitivity of 4 distinct odorants. 
Hormone levels were analyzed using a method of gradient high-performance liquid 
chromatography (HPLC). Multiple analyses yielded a conclusion that the changes in estrogen 
levels influence olfactory ability to an extent that as estrogen levels increase throughout the 
menstrual cycle or peak during the first trimester of pregnancy, olfactory ability is significantly 
heightened (p<.05). This research has provided evidence supporting the idea that hormone levels 
do influence olfactory ability fluctuation during the menstrual cycle and in portions of 
pregnancy. 
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CHAPTER I 
 
INTRODUCTION 
 
 
As human beings, perception of the environment is based on the sensory information 
provided by external stimuli to the five senses. Sight is a product of electromagnetic radiation 
filtering to the retinas in the eyes. The sense of touch is stimulated by the resulting pressure from 
physical contact to an object. Fluctuations in air pressure result in perceiving different sounds. 
The chemical nature in the surroundings informs the senses of taste and smell. These two senses 
are chemically influenced by the most common environmental component – air. Yet, the 
research of these two senses, particularly that of olfaction, is comparatively limited.  
Beyond the external, internally there are multiple facets that influence our perception of 
the environment. One of the major influences of bodily function, and therefore a dominant 
contributor to the perceived world around us is hormones. Hormones, both in type and amount, 
can and do dictate many changes within the body, possibly even, changes in the ability to smell. 
 
Menstrual Cycle 
The possible influence of hormonal state on olfactory function has long been an interest 
of researchers (Doty, Deems & Stellar, 1988).  This interest has led to several studies 
investigating olfactory perception during natural states of hormonal fluctuation and the menstrual 
cycle.   
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Researchers have since studied the menstrual cycle in depth and examined it in a variety 
of ways.  Across various studies the menstrual cycle has been divided into two (e.g., Hertz & 
Jensen, 1975), three (e.g., Englander-Golden, Change, Whitmore & Dienstbier, 1980), four (e.g., 
Graham & Sherwin, 1993), five (e.g., Hart, 1960), and six (e.g., Bancroft, Sanders, Davidson & 
Waller, 1983) phases.  In the current study, four phases of the menstrual cycle will be 
differentiated: follicular phase, ovulation, luteal phase and menses.   
During the menstrual cycle the female body undergoes a variety of changes including 
fluctuations in basal body temperature (Church, Hedricks, LeFevre & McClintock, 1994) and 
hormone levels (Wallen & Zehr, 2004).  In healthy females, gonadal hormone alterations occur 
in a cyclic fashion, changing from phase to phase throughout the menstrual cycle.  The basal 
body temperature, rising and falling as a result of hormonal fluctuation also follows a cyclic 
pattern (Church et al., 1994).  During the first phase of menstruation, the follicular phase, 
estrogen exponentially rises to a peak level relative to each individual’s baseline.  If the basal 
body temperature changes during the follicular phase, a decrease within half a degree will be 
measured.  The relatively high levels of estrogen cause a surge of two hormones: luteinizing 
hormone and follicle-stimulating hormone.  The spike of these two hormones indicates the 
second phase, ovulation.  Upon ovulation, completion estrogen, luteinizing and follicle-
stimulating hormones drop and return to baseline.  Through the development of the third phase, 
the luteal phase, progesterone increases, up to tenfold, and remains consistently high throughout 
the phase.  A rise in estrogen occurs, however, levels do not peak rapidly, nor do they surpass 
those of progesterone.  It is after ovulation, when progesterone is rising, that basal body 
temperatures tend to increase up to a degree and a half above an individual’s baseline.  At the 
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onset of the fourth phase of the menstrual cycle, menses, both estrogen and progesterone levels 
have dropped back to baseline (Reichman, 2009). 
 
Phase Classification 
Studies investigating changes in olfactory perception throughout the menstrual cycle 
typically contribute the changes observed to the phase of menstruation and/or to hormonal 
fluctuations.  To determine the phase of menstruation investigations have used one of five 
methods: self-report of menstrual cycle (e.g., Graham & Sherwin, 1993), measurement of basal 
body temperature (e.g., Watanabe, Umezu & Kurahashi, 2002), characteristics of cervical mucus 
(e.g., Church et al., 1994), urine analysis to determine levels of luteinizing hormones (e.g., 
Lundstrom,	  McClintock & Olsson, 2006), or blood analysis (e.g., O’Leary, Boyne, Flett, Beilby 
& James, 1991). 
 
Olfactory Abilities 
 Upon menstrual phase classification researchers have attempted to understand the 
relationship of the phase of the menstrual cycle and possible changes in olfaction. In general, 
results determining a relationship are heterogeneous. It is proposed that olfactory sensitivity 
increases during ovulation and the luteal phase (Doty, Hall, Flickinger & Sondheimer, 1982; 
Doty, Snyder, Huggins & Lowry, 1981; Le Magnen, 1952; Vierling & Rock, 1967; Mair, 
Bouffard, Engen & Morton, 1978; Navarrete-Palacio, Hudson, Reyes-Guerrero & Guevara-
Guzman, 2003), and decreases during menses (Good, Geary & Engen, 1976; Le Magnen, 1952; 
Mair et al., 1978; Moriyama & Kurahashi, 2000; Navarrete-Palacios et al., 2003; Schneider & 
Wolf, 1955). However, there are conflicting studies. Koster (1968) concluded that olfactory 
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sensitivity improves just before and during menses, while Henkin (1974) found that 
hypersensitivity occurs only during the follicular phase of the menstrual cycle. Derntl, Schopf, 
Kollndorfer and Lanzenberger (2012) reported increased olfactory sensitivity to occur only 
during the luteal phase. Furthermore, several studies have concluded that there are no menstrual 
cycle-dependent alterations in olfaction (Amoore, 1974; Filsinger & Monte, 1986; Herberhold, 
Genkin, Brandle, Leitner & Wollmer, 1982; Hummel, Gollisch, Wildt & Kobai, 1991; Hummel, 
Kobal, Gudziol & Mackay-Sim, 2007; Kanamura & Takashima, 1991).  
 
The Possible Other Use of Oral Contraceptives 
Few studies have attempted to directly correlate hormone level fluctuations during the 
menstrual cycle with olfactory changes. As previously discussed, the determination of a 
relationship between the phase of the menstrual cycle and changes in olfactory sensitivity is 
confused and inconclusive. The measurement of hormone levels has served more as a means of 
phase classification without the continual application and investigation of varying hormone level 
fluctuations and alterations of olfactory sensitivity. Rather, research has moved towards the 
investigation of the impact of oral contraceptives. 
Oral contraceptives affect the human body in varying ways. Most commonly, oral 
contraceptives artificially provide heightened hormone levels to keep the body in a stall state. 
Typically progesterone is the primary component of oral contraceptives. This allows the body to 
remain in a simulated luteal phase until the hormone levels drop. Some oral contraceptives more 
closely mimic the body’s natural menstrual cycle providing a biphasic hormone administration of 
estrogen and progesterone. 
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Caruso, Grillo, Agnello, Maiolino, Intelisann, and Serra (2001) and Doty et al. (1981) 
compared the changes of olfactory sensitivity of oral contraceptive users and non-users. The oral 
contraceptive users were taking a monophasic pill intended to mimic the luteal phase by 
maintaining relatively high levels of progesterone up until the day of ovulation. It was concluded 
that olfactory sensitivity mimicked that of oral contraceptive non-users (Caruso et al., 2001; 
Doty et al., 1981), suggesting that changes in olfactory function during the menstrual cycle are a 
result of something other than fluctuating hormone levels. Lundstrom, McClintock, and Olsson 
(2006) found that oral contraceptive users experienced greater olfactory sensitivity when 
inhaling social odors (e.g., androstadienone) and a decrease in sensitivity when inhaling 
environmental odors (e.g., rose).  
 
The Pregnant Nose 
As research has progressed and the relationship between hormones and olfaction has 
become more complex, the interests have spread to the investigation of olfactory differences 
during pregnancy, the results of which are, to some extent, contradictory (Laska, Koch, Heid & 
Hudson, 1996).  Overall a majority of pregnant women self-report changes in odor perception 
during pregnancy (Ochsenbein- Kölble, von Mering, Zimmermann & Hummel, 2007; 
Wohlgemuth, Beinder, Ochsenbein-Kölble & Hummel, 2008).  While considerable anecdotal 
evidence suggests that pregnant women, when compared to non-pregnant women, are more 
sensitive to odors, objective measurement of this sensitivity is limited and inconclusive. Some 
studies have presented evidence suggesting hypersensitivity during pregnancy (Broman, 
Olofsson, Olsson & Nordin, 2003; Lundström, McClintock & Olsson, 2006; Nordin, Broman, 
Bringlöv & Wulff, 2004).  Yet other studies have concluded that during pregnancy there is no 
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olfactory hypersensitivity (Laska & Teubner, 1999; Swallow et al., 2005).   Furthermore, some 
studies have found hyposensitivity to pervade during pregnancy, while a few have reported the 
occurrence of anosmia (Cameron, 2007). 
 Various studies reporting a change in olfactory sensitivity differ concerning the 
description of the time of maximum effect (Laska et al., 1996).  Le Magnen (1952) concludes 
that pregnant women experience an increase in odor sensitivity during the first trimester, while 
Good, Geary and Engen (1976) stipulate hypersensitivity to occur predominantly throughout the 
second and third trimesters.  Very few studies have emphasized or even included the third 
trimester of pregnancy during investigation (Ochsenbein-Kölble et al., 2007).  Of these, some 
investigators report a decreased sensitivity later in pregnancy when compared to non-pregnant 
controls (e.g. Laska et al., 1996; Wohlgemuth et al., 2008), while Nordin, Broman, Bringlöv and 
Wulff (2007) specify that changes in olfactory sensitivity rarely occur late in pregnancy.  
 
Odor Sensitivity 
It should be noted that the aforementioned studies differ in the operational definition of 
odorant sensitivity.  For example, Nordin et al. (2004) write of sensitivity in relation to odor 
identification, whereas Laska et al. (1996) discuss sensitivity in terms of ability to sense the 
presence of any odor.  The current study refers to sensitivity as the latter.  Before a certain 
threshold there should be no odorant detection.  Above its threshold, the perception of an odor 
increases in magnitude relative to the increase of odor concentration (Walker, Hall, Walker, 
Kendal-Reed, Hood & Niu, 2003).  
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Evolution Could Be the Key 
The potential changes in olfaction sensitivity during pregnancy could be due to 
strengthened hormonally modulated connections between the limbic system and the olfactory 
system (Cameron, 2007; Wohlgemuth et al., 2008), or this resulting effect could be in response 
to changes in the cognitive information processing of odorants (Kölble, Hummel, von Mering, 
Huch & Huch, 2001; Zou, Li & Buck, 2005).  Cameron (2007) postulates that the foundation for 
odor detection may be more drastic during pregnancy.  That is to say that a small change in odor 
concentration that may go unnoticed by non-pregnant women might result in a large change in 
odor intensity perception for pregnant women (Cameron, 2007).  This enhanced odor sensitivity 
could provide an evolutionary advantage, discouraging pregnant women from ingesting 
potentially noxious substances that could be harmful to a developing fetus (Heinrichs, 2002; 
Profet, 1992) or enriching the perceived attractiveness of a pregnant woman’s mate 
(Wohlgemuth et al., 2008). 
 Evolutionarily female fertility, in large part dictated by the endocrine system’s regulation 
of gonadal hormones, has evolved to emphasize certain hormonal phases (Wallen & Zehr, 2004).   
During a normal, healthy pregnancy this regulation tends to develop in a uniform manner.  
Studies have shown an increase in a multitude of hormones in varying amounts throughout 
pregnancy.  These hormones include estradiol, progesterone, testosterone, sex-binding-hormone 
globulin, androstenedione and 17-hydroxyprogesterone.  A decrease in dehydroeplandrosterone 
sulfate has also been reported (O’Leary et al., 1991). 
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Neglected but Not Forgotten 
The research conducted thus far examining the pregnant population has neglected the 
consideration or the empirical measure of hormonal changes experienced by pregnant females 
and how said changes influence olfaction.  Hormonal fluctuations seemingly dictate much of the 
olfactory perception change during the menstrual cycle.  The hormone changes that occur during 
pregnancy could exhibit the same type of influence over the olfactory system. 
There is certain, albeit not entirely conclusive, support for the idea that pregnant women 
perceive some odorous substances as stronger than do non-pregnant women (Nordin et al., 
2004).  Also, as mentioned previously, Lundstrom et al. (2006) discussed evidence for women 
taking oral contraceptives sense some odorants more readily than others.  
 
The Present Study 
The literature is suggestive but contradictory and inconclusive concerning the effects of 
hormones on olfactory perception, particularly odorant sensitivity.  The present study has been 
designed to examine this effect based on specific odorants and measured olfactory ability. 
 
Odorants 
In the current study, four odorants will be used – vanillin, caraway, spearmint and 
muscone – to assess olfactory ability. The odors were selected based on the diverse properties 
they possess. The odors differ by their molecular classifications as well as in their perceived 
qualities (e.g., sweet, pungent). The chemical formula and structure can be found in Appendix A.  
Muscone is a non-polar, 15-carbon ring with a ketone functional group. Muscone is a 
territorial pheromone in musk deer (Jacob, Garcia, Hayreh, & McClintock, 2002), and has an 
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odor similar to sweet, pungent fresh earth. The chemical structure of non-polar compounds 
allows for the odorant to diffuse across the mucus membrane in the nose without the direct aid of 
olfactory binding proteins. In addition, muscone has been chosen because, even in high 
concentrations, it does not activate the trigeminal nerve (Jacob et al., 2002). Avoiding activation 
of the trigeminal nerve ensures that only odorant sensitivity is assessed (Doty, 2001). 
 Vanillin, unlike muscone, is a polar molecule used in commercial products throughout 
the United States. Vanillin exudes a characteristic pleasant, sweet aroma. It is also one of the first 
odors to be recognized and preferred by infants (Edraki, Pourpulad, Kargar, Pishva, Zare & 
Montaseri, 2013). Polar molecules require olfactory binding proteins to transport them across the 
mucus membrane. If hormone levels affect the availability or binding process of the olfactory 
binding proteins or olfactory binding receptors, examining the effects of both a polar and non-
polar molecules has the potential to lend insight. 
 Caraway and spearmint each contain an optical isomer, or enantiomer, carvone. The 
enantiomers of carvone share an isopropenyl group at the chiral carbon, allowing for this 
enantiomer to differ in odor quality (Bentley, 2006; Laska, 2004). Receptors in the body are 
stereoselective and, as a result, typically react with only one of the compounds of an enantiomer 
pair. Each enantiomer, due to three dimensional molecule arrangement differences, binds to the 
odor receptors in a different and specific way, hence the different perception of spearmint and 
caraway odors. R-(-)-carvone is perceived to have the fresh, minty odor quality synonymous 
with spearmint, while the S-(+)-carvone odor is caraway and dill-like with a peppery undertone. 
Carvone enantiomeric odor pairs have also been shown to not be mediated by the activation of 
the trigeminal nerve (Laska & Teubner, 1999).  
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The chirality of these enantiomers is an aspect of olfaction unexamined in the pregnant 
population or within the context of the menstrual cycle. The perception of different odorant 
properties for these two enantiomers lends support toward olfactory receptors containing chiral 
groups that allow for a stronger response to one enantiomer compared to the other. 
 
Hypotheses 
The present study has been designed to examine the effect of hormones on the olfactory 
abilities of women on four levels by using the four aforementioned odorants. The first level 
examines olfactory perception across all trimesters of pregnancy, and the second is a comparison 
of olfactory ability between two groups: pregnant and non-pregnant women.  The third and 
fourth levels of investigation are a comparison of the differences of odorant perception during 
the menstrual cycle and during pregnancy. The hypotheses are as follows: 
Hypothesis 1: Women will experience higher levels of olfactory sensitivity and have 
lower threshold levels for all odorants as a result of increased estrogen levels. 
Hypothesis 2: Overall, oral contraceptive users will have greater olfactory sensitivity and 
lower thresholds while taking the active hormone pill when compared to oral contraceptive users 
in menses. 
Hypothesis 3: Olfactory abilities will decrease throughout pregnancy. 
3a. Odorant thresholds will increase throughout pregnancy; therefore those at the 
beginning of pregnancy will have lower odorant thresholds than those toward 
the end of pregnancy. 
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3b. Olfactory sensitivity will decrease throughout pregnancy; therefore olfactory 
sensitivity will be higher at the beginning of pregnancy than toward the end of 
pregnancy. 
Hypothesis 4: Pregnant women will have a greater olfactory sensitivity, thus a lower 
threshold, when compared to non-pregnant controls. 
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CHAPTER II 
 
METHOD 
 
 
 The current study was conducted at two different time measurements. Assessment one 
data was collected in late November, and assessment two data was collected in the middle of 
December. 
 
Participants 
 During part one of the assessment, 72 non-pregnant, female participants ages 18 to 43 
years old (M=20.11, SD=3.388) and seven pregnant participants ages 29 to 41 (M=34.86, 
SD=4.488) were recruited from the University of Tennessee at Chattanooga campus and a 
medium size obstetrics and gynecology clinic in Chattanooga, Tennessee. Part two of the 
experiment received a total of 62 of the original 72 non-pregnant participants ages 18-41 
(M=20.21, SD=3.599) and all seven of the pregnant participants returning for assessment. An 
overview of where each pregnant participant self-reported to be within pregnancy can be found 
in Table 2.1. Also, a summary of self-reported ethnicities of non-pregnant participants can be 
found in Table 2.2. It should be noted that each pregnant participant self-reported as Caucasian. 
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Table 2.1 Pregnancy Trimester During Assessment 
Participant Trimester at 
Assessment 1 
Trimester at 
Assessment 2 
1 1 1 
2 1 2 
3 1 2 
4 2 3 
5 2 3 
6 2 3 
7 3 3 
 
 
Table 2.2 Ethnicity of Non-Pregnant Participants at Assessment One and Two 
 
Ethnicity Assessment 1  Assessment 2  
 Frequency Percent Frequency Percent 
Caucasian 51 70.83 44 70.97 
African American 10 13.89 9 14.52 
Bi-Racial 5 6.94 4 6.45 
Latina 3 4.17 2 3.22 
Middle Eastern 2 2.78 2 3.22 
Asian 1 1.38 1 1.61 
 
 
Participants were asked to complete a demographic questionnaire (Appendix B) to 
ascertain details about past and current health at both assessment one and two. Questions 
concerned such things as smoking habits, past and current diseases and disorders, medications, 
menstruation and pregnancy history. A depiction of this data is shown in Table 2.2 for both part 
one and part two of the experiment. Upon completion of the second assessment, participants 
were given a non-transferrable, fifteen-dollar gift card from a local business. 
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Table 2.3  Health History Data for Non-Pregnant Participants at Assessment One and Two 
 
 
 
0	   5	   10	   15	   20	   25	   30	  Other	  Medical	  Illnesses	  
Ulcer	  Thyroid	  Disorder	  
TB	  Stroke	  
Sleep	  Apnea	  Skin	  Disease	  
Sinus	  Problems	  Seasonal	  Allergies	  
Neurological	  Disease	  Medical	  Allergies	  
Lung	  Trouble	  Kidney	  Disease	  
Infection	  HIV	  
High	  BP	  Hiatal	  Hernia	  
Hepatitis	  Heart	  Disease	  
Gout	  Food	  Allergies	  
Eye	  Disease	  Epilepsy	  
Diabetes	  Deviated	  Septum	  
Concussion/Head	  Trauma	  Circulation	  Problems	  
Chronic	  Headaches	  Cancer	  
Broken	  Nose	  Bleeding/Clotting	  Disorder	  
Asthma	  Arthritis	  
Anemia	  
Time	  1	  Time	  2	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Review Board 
 The current study has been approved by the University of Tennessee at Chattanooga 
Institutional Review Board (Appendix C). In compliance with this approval all data, including 
blood analysis results, threshold data and demographic information were kept confidential and 
stored in an encrypted data file.  
 
Protection of Health Information 
 Prior to beginning data collection, all researches involved were required to complete 
HIPPA training and become HIPPA certified. Also, researchers were required to complete NIH 
and CITI certifications before having access to participant information collected during 
assessment. 
 
Materials and Procedures 
Modification of the WUTC 
 The original Wheeler-University of Tennessee at Chattanooga (WUTC) threshold test 
(Tewalt, 2013) contained five odorants: ethanol, L-α-pinene, vanillin, isoamyl acetate, and p-
cresol. For the current study, an odorant modified WUTC threshold test was used. Four distinct 
odorants were selected in the modification of the WUTC threshold test: vanillin, R-(-)-carvone, 
S-(+)-carvone, and muscone. Each of these odorants was selected for a distinct reason as 
described previously.   
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Odorant Dilutions 
 In making the modified WUTC threshold test, each odorant molecule was dissolved, 
based on each molecule’s individual solubility, in a purified water solvent to create a maximum 
concentration standard dilution that appeared to be visually translucent and clear. A 1:3 
geometric serial dilution of the standard solution was used to create a total of nine concentrations 
for each odorant. The dilutions were made to allow for the middle odorant tube to contain a 
dilution equivalent to that of reported threshold detection norms. Ten milliliters of each dilution 
were contained in a sterilized glass vial. Appearance of the liquid, regardless of odorant or 
concentration, remained translucent and clear in nature. In total, the WUTC threshold test 
contained nine varying concentrations of each of the four odorants for a total of thirty-six 
odorant vials. In addition, nine non-odorous, “blank” vials were included.  Blanks were made 
using ten milliliters of purified water. The final, modified version of the WUTC threshold test 
contained forty-five separate vials of varying concentrations of four odorants and blanks. 
 
Threshold Test Administration 
 During parts one and two, participants completed the WUTC threshold test. At each 
presentation of the threshold test, two researchers were present. Because carry over effects from 
one assessment to the next can be an issue when assessing participants in a longitudinal fashion, 
participants were informed that the tubes would be presented in a random order at each test 
administration. Participants were also told that some tubes could have detectable odorants, some 
could have odorants that might not be potent enough to perceive, and some could have no 
odorant present. Once participants had read through and signed an informed consent specific to 
the threshold test (Appendix D), they were asked to sit, facing away from the researchers. 
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Participants were randomly presented with 10mL of each dilution for a total of 5 seconds at a 
distance of about 2 cm below the participant’s nose by a researcher using a test tube holder.  
Upon retraction of the odorant dilution the participant was allowed 10 seconds to indicate, by 
stating “yes” or “no”, if an odor had been detected.  Out of the line of sight of the participant, a 
second researcher recorded the indications appropriately.  This second researcher was also 
responsible for preparing the next tube in the randomized order for the administering researcher.  
In this way the administration of the test tubes was double blind.  The test was considered 
complete when the participant had given a response for all odorant dilutions and blanks. 
 
Blood Collection 
 Prior to completing the modified WUTC threshold test, blood was drawn from each 
participant during both parts of the experiment for the purpose of ascertaining estrogen hormone 
levels at the time of participation. Blood Assurance of Chattanooga agreed to draw 10 milliliters 
of blood from each participant during parts one and two of the experiment. In cooperation with 
Blood Assurance of Chattanooga, all non-pregnant participants were asked to attempt to donate 
blood prior to the draw of the first required 10 milliliter sample, and each participant was 
required to complete two informed consent forms, one specific to the 10 milliliters vial blood 
draw as a part of the study (Appendix E) and one provided by the staff at Blood Assurance of 
Chattanooga (Appendix F). 
 Blood withdrawals followed the standardized procedures set by Blood Assurance. After 
the 10 milliliters of blood was drawn into a sealed, sterilized vial, each vial was labeled with a 
six digit serial number. This vial number was then transferred to a master document and to the 
participants’ specified threshold test response sheet for the purposes of linking any results 
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obtained from the blood analysis to individual threshold data. Once the blood was obtained from 
each participant for part one of the experiment it was stored at a constant temperature of -80 
degrees Celsius for optimal preservation.  
Three weeks after the completion of the first part of the experiment participants 
completed the second portion of the research. This portion of the study mimicked the material 
and procedures of part one, with the exception that no one was asked to donate blood prior to 
their blood draw. After 10 milliliters of blood was obtained from each participant, each vial was 
labeled with the same six digit serial number assigned to the participants during their 
participation in part one as recorded on the master list. To identify which blood sample was 
drawn first and which second for any given participant an 11 or 12 was recorded on the first and 
second blood draw vials respectively. Once serial numbers were confirmed to match the master 
list linking participants’ names to the blood vial, the master list of serial numbers was destroyed 
to protect participant confidentiality. 
A total of 148 blood samples (10 milliliters) were stored in a freezer at the University of 
Tennessee at Chattanooga in the biochemistry lab. 
 
Blood Analysis 
 The blood samples were analyzed through multiple procedures in randomized batches. 
Four days prior to the start of blood analysis vials were selected from the freezer and placed in a 
refrigerator. This allowed for the blood samples to slowly thaw to a temperature of 4 degrees 
Celsius. Once thawed one milliliter aliquots of each sample were drawn from each vial using a 
single, sterilized syringe and needle. The samples were subjected, six at a time, to 
ultracentrifugation in a Centrifree Micropartition device with a 30,000 Dalton cut-off membrane 
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at 2000 xg for 30 minutes. The filtrate samples were then diluted with purified methanol 
(CH3OH ) to make a one milliliter mixture. Each diluted filtrate sample was then labeled with a 
matched, six digit serial number and stored at 25 degrees Celsius prior to further analysis. 
 Standard solutions were made to contain single molecules of estradiol in varying 
concentrations with methanol in order to verify the detection of estradiol molecules based on 
determined retention time and corresponding peak height and area. After confirming detection 
criteria the refrigerated filtrate mixtures were analyzed using a Reversed-Phase High 
Performance Liquid Chromatography (HPLC) to separate the molecular components in the 
mixture. The instrument was equipped with a stationary phase 250-millimeter x 4.6-millimeter 
Porshell II (void volume of 1.5 milliliters); the mobile phase buffer used in separation was 
HPLC-grade methanol. A five minute column pre-clean, using methanol, was performed prior to 
each set of analyses. Also, the syringe was washed with methanol and HPLC-grade water prior 
to each analysis to avoid cross-contamination. 
 The 15 microliter injection of each filtrate mixture was loaded onto the column and 
subjected to elution for 5 minutes at a flow rate of 1milliliter/minute by the methanol buffer. 
Component molecules of the filtrate mixture were detected by ultraviolet absorbance using a 
deuterium lamp at wavelengths of 280 nanometers – the wavelength at which aromatic proteins 
(e.g., estradiol) typically absorb. Because proteins also absorb at 214 nanometers, and organic 
compounds, like estradiol, absorb at 254 nanometers, each of these wavelengths was also 
observed. No significant differences were observed in the elution chromatograms at 214 or 254 
nanometers compared to the detection profile at 280 nanometers. 
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CHAPTER III 
 
RESULTS 
 
 
Analysis 
Blood Analysis 
 To determine levels of estrogen in the blood of participants at the time of completing the 
threshold test, samples were analyzed with an HPLC. Retention times and peaks at 280 
nanometers for each sample were compared to that of the standard solutions also analyzed during 
the same time period. The retention time as well as the peak areas recorded varied analysis to 
analysis, requiring the standard solutions to be measured during each sample batch analysis. This 
variation can be due to factors such as ambient pressure and temperature and fluctuating pressure 
within the HPLC.  
The analysis of these five standard solutions composed of varying levels of estradiol 
resulted in five peak areas from similar retention times in the HPLC output (Figure 3.1).  
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Figure 3.1 Example of HPLC Output Data 
 
The correlation of concentration to peak area resulted in Pearson r values indicating a 
strong, positive relationship each time of blood analysis (Table 3.1). A scatterplot of 
concentration versus peak area was created for each measurement of the standard solutions, from 
which a prediction equation was determined.  
 
 
Table 3.1 Relationship of Standard Solution Concentration to Peak Area 
 
Blood Analysis Pearson r Significance Level (p) 
Measurement 1 .987 .006 
Measurement 2 .994 .001 
Measurement 3 .999 <.001 
Measurement 4 .997 <.001 
Measurement 5 .996 <.001 
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Retention times within one tenth of a minute to that of the estradiol standard solutions 
were considered to be indicative of estrogen within the sample. These retention times and the 
corresponding peak areas were recorded. Each sample resulted in one peak area number that was 
then plugged into the equation determined from the standard solutions. This raw concentration 
value was then multiplied by the dilution factor by which each sample was specifically made. 
This final value is the estimated estrogen concentration for the analyzed blood sample. 
 
Olfactory Ability Analysis 
 The modified WUTC threshold test was evaluated using multiple statistical tests. In total 
the threshold test is able to describe each participant’s and group’s olfactory ability in three 
distinct ways for each of the four odorants. These measures include threshold, sensitivity and 
response bias.  
 An estimated odorant threshold of each of the odors, vanillin, caraway, spearmint and 
muscone was obtained. To determine threshold values the “yes” and “no” responses were 
analyzed using logistic regression. The predicted values generated from the logistic regression 
were then graphically represented and the estimated threshold value was determined to be the 
odorant concentration value that corresponded to a p-value of 0.5 on the sigmoid curve. 
 To measure olfactory sensitivity the d’ statistic was calculated. The d’ statistic allowed 
for a representation of the differences in sensitivity to different odorants. This value is calculated 
by determining the difference between the z-scores of the hit and false alarm rates. To be 
considered a “hit” an individual must indicate a “yes” during the threshold test when a vial with 
an odorant concentration was presented. Inversely, a “false alarm” results when an individual 
23 
responds “yes” when a vial with no odorant is presented. The d’ value was calculated by the 
following equation (Macmillan, 1993): 
d’=z(H)-z(F) 
 The values for the d’ statistic range from zero to 4.65 (Tewalt, 2013). The lower the 
value, the lower the sensitivity to an odorant, and the higher the value, the more sensitive to an 
odorant a participant is thought to be. Sensitivity was calculated for each participant for each of 
the four odorants of the threshold test. Their overall sensitivity to all four odorants was also 
calculated. Therefore, for one administration each participant produced a total of five sensitivity 
values. 
 As a way to measure the tendency of a person to respond to the presentation of a tube 
with either a yes or a no, regardless of whether an odorant was presented or not, response bias 
was calculated. The B’’ value is defined by the equation (Stanislaw & Todorov, 1999): 
 
B’’ was calculated as a measure of response bias rather than the standard response bias 
measure β due to B’’ independence to the changes in d’ (Stanislaw & Todorov, 1999). A 
measurement of response bias was calculated for each participant for both assessments. 
To determine respondent reliability, each participant’s response data was split into first 
and second administrations for each odor. The reliability statistic Cohen’s kappa was then 
computed to determine the reliability of each participant’s dichotomous, “yes”/”no” responses. 
Additionally, the reliability for each odorant was calculated.   
Demographics collected from each participant were analyzed for the existence of 
relationships with all calculated measures.  
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Statistical Results 
Estrogen Concentration and Olfactory Ability 
In order to assess the relationship of estrogen levels (Table 3.2)  to olfactory sensitivity 
and estimated threshold values linear regressions were employed for each odorant. No significant 
differences were found for sensitivity levels for individual odorants. However, there was a trend 
for estrogen levels and overall olfactory sensitivity was determined (t = 2.085, p = .074). Two 
specific odorant thresholds were determined to be significantly related to and predicted by 
estrogen levels in the blood. Spearmint was found to have a moderately strong negative 
relationship with estrogen level (r = -.386, p = .001). A significant result of t = -3.359, p = .001 
was also found. A second odorant, muscone, was determined to also have a moderately strong 
negative relationship (r = -.318, p = .001) with estrogen levels significantly predicting the 
threshold levels of both pregnant and non-pregnant participants (t = -3.162, p = .002).  
 
Table 3.2 Estrogen Concentration Levels 
 Minimum 
(mg/mL) 
Maximum 
(mg/mL) 
Mean 
(mg/mL) 
Std. Dev. 
(mg/mL) 
Estrogen Concentration Levels .01 21.24 4.28 4.56 
 
 
Due to lack of significance in the relationship of individual odorant sensitivity and 
estrogen levels, response bias was taken into account. Firstly, it was found that response biases 
are moderate to strongly related (r = .623, p < .001) to sensitivity with a significantly predictive 
relationship (t = 9.141, p < .001). Response bias per odorant and overall was assessed in 
comparison with estrogen levels. Interestingly results indicate a significant, moderately strong 
relationship between estrogen concentrations in the blood and overall response bias                     
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(r = -.404, p < .001), vanillin response bias (r = -.307, p = .002), caraway response bias              
(r = -.401, p < .001), spearmint response bias (r =. 348, p = .001), and muscone response bias    
(r = .304, p < .001). Thus, when a participant has a response bias to “yes” they tend to also have 
relatively elevated blood estrogen levels. 
Reliability between each threshold administration test half was assessed with the use of 
Cohen’s kappa. The results of the analyses are presented in Table 3.3.  
 
Table 3.3 Reliability Measure between Test Halves (Cohen’s kappa) 
Odorant Threshold 
Vanillin 0.727 
Caraway 0.301 
Spearmint 0.643 
Muscone 0.701 
 
 
Oral Contraceptive and Olfaction 
A paired sample t-test was used to assess the differences of olfactory ability between 
participants while taking the active hormone pill of their oral contraceptive and while in menses 
(i.e., taking the inactive hormone pill). A total of 17 women (27.4%) of the 62 that participated in 
both assessments were taking oral contraceptives. To be included in analysis the women self-
reported being in menses during one of the two assessment times and not in menses during the 
other. No significant differences were found between the mean threshold values or sensitivities 
for individual odorants, nor of overall odorant sensitivity. 
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Olfactory Abilities during Pregnancy 
 Changes in olfactory ability throughout pregnancy were analyzed with a one-way within-
subjects analysis of variance. The means and standard deviations for sensitivity and estimated 
threshold values are presented in Table 3.3 and Table 3.4 respectively. Vanillin sensitivity        
(F (1, 6) = 5.282, p = .049) with a partial eta of 0.568, vanillin threshold (F (1, 6) = 6.274,          
p = .046) with a partial eta of 0.611, and muscone threshold (F (1, 6) = 6.681, p = .042) with a 
partial eta of 0.627 all significantly changed as women progressed in their pregnancies. This can 
be seen in Figures 3.2, 3.3, and 3.4. A trending significance was found for spearmint sensitivity 
(F( 1, 6) = 4.16, p = .078), which can be seen in Figure 3.5. It should be noted that there is little 
difference between the mean values of the second and third trimesters. This suggests that 
olfactory abilities are better in early pregnancy. 
 
 
Table 3.4 Assessment One and Two Olfactory Sensitivities 
 
Measure Assessment 1  Assessment 2  
 Mean Std. Dev. Mean Std. Dev. 
Overall 1.16 1.14 .95 1.18 
Vanillin 2.19 1.61 1.17 1.06 
Caraway .77 .53 .70 .45 
Spearmint .75 .56 .43 .63 
Muscone 1.09 1.19 .97 1.24 
 
 
 
 
Table 3.5 Assessment One and Two Estimated Threshold Values 
 
Measure Assessment 1  Assessment 2  
 M Std. Dev. M Std. Dev. 
Vanillin 2.97 2.75 10.61 7.23 
Caraway 237.94 299.63 727.39 1064.05 
Spearmint 671.46 1144.98 1122.33 1483.54 
Muscone 366.34 530.64 883.71 890.73 
27 
 
 
 
Figure 3.2 Vanillin Sensitivity During Pregnancy 
 
 
 
 
Figure 3.3 Estimated Vanillin Threshold Values During Pregnancy 
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Figure 3.4 Estimated Muscone Threshold Values During Pregnancy 
 
 
Figure 3.5 Spearmint Sensitivity During Pregnancy 
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Pregnant Versus Non-Pregnant 
 An analysis was conducted to determine if olfactory ability was differed for pregnant and 
non-pregnant individuals. Results indicate that there is a significant difference in the threshold 
levels of spearmint, with pregnant women having a lower mean estimated threshold (t = 2.097,   
p = .006). This difference is also noted with caraway thresholds (t = 2.029, p = .044). To 
examine possible explanations a comparison of estrogen levels was made. Overall estrogen 
levels seem to be similar during pregnancy to the levels experienced by the women on their 
menstrual cycle, with one exception being that women in the first trimester of pregnancy have 
slightly higher estrogen levels than non-pregnant participants (t = 1.981, p = .098) 
 
Demographic Relations 
Demographic data were also analyzed to determine if any significant correlations existed 
between the self-report measure and the olfactory ability measures of sensitivity, threshold and 
response bias. Caraway sensitivity was found to be weakly related to instances of self-reported 
chronic headaches (r = -.249, p = .036) and high blood pressure (r = -.291, p = .037). Muscone 
sensitivity was moderately related to a previous history of cancer (r = -.496, p = .001). 
Interestingly spearmint sensitivity is the only odorant sensitivity related to self-reported nose 
problems, including having a broken nose (r = -.315, p = .013) and a deviated septum (r = -.281, 
p = .026). Each relationship discovered with sensitivity is negative in nature; that is to say that 
sensitivity has a trend of being lower in those individuals that are currently or have previously 
experienced the aforementioned health related issues. 
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Overall response bias and response bias for each individual odorant was noted to be 
significant, but weakly relate (p < .05) to a health history of cancer. Individuals that were taking 
antihistamines at the time of assessment, as well as those that were experiencing some type of 
infection, including sinus infections, were noted to have moderately strong response bias overall 
and for each of the four odorants at a significance of p < .05 (Table 3.6) 
 
Table 3.6 Response Bias and Infection 
Response Bias and Infection Pearson r p value 
Vanillin .363 .031 
Caraway .301 .020 
Muscone .380 .037 
Spearmint .376 .042 
Overall .387 .031 
 
 
Alternatively, estimated thresholds were compared to self-reported infections with 
spearmint threshold. These threshold levels tended to increase, mean ability to smell decreased, 
with reported infections. When comparing threshold levels to medications taken at the time of 
assessment, muscone threshold levels were moderately, positively related to taking 
antidepressant (r = .335, p = .004) and antianxiety (r = .347, p = .007) medications. 
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CHAPTER IV 
 
DISCUSSION 
 
 
 The purpose of the current study was to investigate the relationship of estrogen levels on 
the olfactory abilities of women. In an attempt to comprehensively understand this possible 
relationship, two populations were examined: pregnant and non-pregnant women. Each of these 
populations experiences characteristic changes in hormone levels, particularly estrogen, either 
during menstruation in non-pregnant women or throughout three trimesters in pregnant 
participants. In general, it was found that estrogen levels do, in some fashion, influence olfactory 
abilities. 
 Olfactory ability, as measured by odorant sensitivity, estimated odorant threshold values 
and response bias, was seen to change as estrogen levels fluctuated. In fact, a trend of overall 
olfactory sensitivity increasing as estrogen levels increased was noted. Given that further 
distinctions were found, this expresses that a woman’s ability to sense the presence of an odorant 
is, in part, influenced by her hormone levels. To understand what other factors could influence 
sensitivity, response bias, was examined for each participant. As expected, response bias 
influences an individual’s measured sensitivity. Women with a response bias towards “yes” 
tended to have higher reported olfactory sensitivities, while those with a response bias towards 
“no” reported a lower sensitivity, or ability, to detect odors. 
 Potential influences of response bias were examined, and, surprisingly, it was found that 
estrogen levels could play a key role. In fact, individual and overall odorant response biases were 
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found to have a strong relationship with estrogen levels. This could be a revealing aspect of 
hormonal influences on factors outside the specified purview of the olfactory system. As 
estrogen levels fluctuate, response biases countered this trend. That is to say that as a woman’s 
estrogen levels increased, her response bias decreased. If response bias does not remain the same 
for an individual, it is possible that response bias is a mediating factor of estrogen levels and 
olfactory sensitivity.  
Two odorant thresholds, spearmint and muscone, were found to decrease as estrogen 
levels increased. This indicates that as more estrogen circulates through the body, like during the 
follicular and luteal phases of menstruation and during the first trimester of pregnancy, a 
women’s ability to smell spearmint and muscone is elevated. Due to chiral recognition that 
occurs with stereoselective receptors, it is not surprising that one of the enantiomer pairs, 
spearmint, is influenced by estrogen levels while caraway seemingly is not. Estrogen levels are 
thought to alter the availability of olfactory binding proteins and receptors, but how and in what 
magnitude these alterations occur is yet unknown. Results indicate that a woman’s ability to 
detect spearmint increases as estrogen levels increase. This could intimate a relationship of 
estrogen level influence on specific, stereoselective olfactory binding proteins or receptors. 
Muscone, being a non-polar molecule, diffuses across the mucus membrane without the 
assistance of olfactory binding proteins. While changes in hormone levels have been shown to 
influence the mucus membrane of the uterus, little research has been conducted to investigate if 
the mucus membrane of the nasal cavity thins and thickens with any regularity. If the thickness 
of the membrane is not a probable cause of the improvement of a woman’s ability to detect 
muscone as estrogen levels increase, then, from an evolutionary perspective, the ability to smell 
a social odor, like musk, could be a result of a woman’s body preparing for the optimal 
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fertilization period. Lundstrom, McClintock, and Olsson (2006) found that oral contraceptive 
users experienced greater olfactory sensitivity when inhaling social odors. Despite there being no 
relationship between oral contraceptive use and olfactory ability in the current study, it is thought 
that the relatively high levels of estrogen could have influenced the distinction between social 
and environmental odors, and therefore resulted in the decreased olfactory thresholds for 
muscone while estrogen levels were relatively high. 
 Wohlgemuth, et. al. (2008) found that pregnant women self-reported heightened olfactory 
sensitivity to multiple odors, including those prominently composed of musk-like components. 
Little research has been conducted to examine if an objective change in olfactory ability occurs 
once pregnant, or if it is simply a perceived self-report phenomenon. In the current study it was 
found that, in fact, there is a difference in olfactory ability as measured by odorant sensitivity and 
estimated threshold values, for some odorants, between pregnant and non-pregnant participants. 
In general, it was determined that estrogen levels of the women in their first trimester of 
pregnancy superseded those of non-pregnant women. These higher level of estrogen indicate the 
expected lower mean thresholds of spearmint and caraway in the pregnant participants. 
 Self-report changes in olfactory perception show pregnant women reporting several 
changes, many of which relate to the odor qualities of spearmint and caraway. The odor of minty 
toothpaste is one of the most commonly reported stimulant causes of morning sickness during 
pregnancy (Wohlgemuth, et. al., 2008). Also, pungent and mildew-like odors have been reported 
to smell more strongly and perceived as more negative in pregnant populations (Ochsenbein- 
Kölble, et. al., 2007). These self-reported heightened sensitivities to mint and stale type odors 
could in fact be due to a measureable difference in a pregnant women’s ability to smell. 
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 It has been postulated that olfactory ability might be improved for toxic or harmful odors, 
especially during the first trimester of fetal development, to possibly hinder any negative 
influences that could cause developmental issues during this rapid growth period. To resolve if 
olfactory abilities remained heightened throughout pregnancy, participants were assessed at two 
time points within pregnancy. It was found that during the first trimester vanillin sensitivities and 
thresholds, as well as muscone thresholds, all were heightened when compared to the second and 
third trimesters. It has been concluded that while olfactory ability does improve for a short time 
during pregnancy, the first trimester is the only time that this occurs. It is thought that the 
olfactory abilities during the second and third trimesters more closely resemble that of non-
pregnant women. 
 Through the examination of demographic data, further relationships of olfactory ability 
were discovered. It was found that odorant sensitivity is related to numerous health issues. 
Spearmint sensitivity was found to significantly relate to having a previously broken nose or a 
deviated septum. This is unsurprising due to the changes the nasal cavity experiences due to 
these physical alterations. For example, a previously broken nose or deviated septum could result 
in less air flow across the mucosal membrane, thus preventing an adequate amount of odorant to 
readily diffuse across the membrane for interpretation. Caraway sensitivity was found to be 
weakly related to both high blood pressure and reports of chronic headaches. High blood 
pressure can result in a thickening of the nasal mucosa and a development of persistent or 
chronic headaches. In addition, chronic headaches can yield symptoms of swelling of nasal 
epithelium and the thickening of the nasal mucus membrane (Chow, 1993). In both instances, 
odorants could encounter diffusion or binding problems.  
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Muscone was noted to have a moderate relationship with cancer, it is unclear why cancer 
would influence muscone sensitivity specifically. Knowing the type of cancer could shed further 
light on the relationship, but was outside of the scope of the provided demographic. Estrogen has 
been found to stimulate breast tissue cell growth and to influences certain blood vessel cancers, 
vaginal cancer, and melanoma (Ito, Utsunomiya, Yaegashi & Sasano, 2007). 
 A history of cancer was also related to response bias, as well as those suffering from an 
infection at the time of assessment. It is thought that individuals suffering from some type of 
infection, particularly those infections resulting in cold or allergy like symptoms, would, as 
found, have an increased response bias towards yes. Participants often want to do well on a given 
assessment, but, when they perceive their abilities to be stunted by environmental factors, like a 
cold, during a test that is assessing one’s ability to smell, many participants seemed to 
compensate by indicating a “yes” more often than they actually smelled an odorant. Despite this 
response bias towards responding “yes”, spearmint threshold levels still tended to increase in 
those with self-reported infections.  
When comparing threshold levels to medications taken at the time of assessment it was 
found that individuals taking anti-anxiety and anti-depressant medications had higher muscone 
threshold levels. Areas of the brain that are involved in depression also overlap with areas 
responsible for olfactory perception (Naudin, El-Hage, Gomes, Gaillard, Belzung, & Atanasova, 
2012). Assuming individuals taking anti-depressant medications have been diagnosed with 
depression, this overlap in brain region could explain why, when depression is present, olfactory 
abilities are not as acute as they could be.  
A final significant relationship was found when examining medication and olfactory 
abilities. It was found that taking antihistamines related to response bias overall and for each 
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individual odorant. This can again be attributed to a participants attempt to be perceived as 
performing well. It stands to reason that an individual taking antihistamines is most likely 
suffering from allergy or cold-like symptom. If they are experiencing nasal congestion, but want 
to be perceived as doing well on an olfactory test, their response bias is expected to shift, as it 
did in the current study. Surprisingly, having seasonal allergies did not show a relationship with 
olfactory ability. However, because assessment one was conducted in late November and 
assessment two was conducted in mid-December, very few, if any, seasonal allergies would have 
been present in the external environment. 
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CHAPTER V 
 
CONCLUSIONS 
 
 
 Overall, differences were found in the various measures of olfactory ability implemented 
in the current study, leading to the conclusion that hormone levels, specifically estrogen, do 
influence olfactory abilities. 
 
Limitations and Directions of Future Research 
Assessment Time 
 While the sample size for non-pregnant participants in the current study is one of the 
largest known samples, a major limitation to analysis, was the number of times participants were 
assessed. Each participant, pregnant and non-pregnant alike, was assess twice. Each pregnant 
participant was assessed six weeks from time one and time two in the hopes of allowing for two 
distinct time measurements across two different trimesters of each of their pregnancies. The non-
pregnant participants were assessed a total of three weeks apart from time one to time two. While 
this allowed for a distinction to be made between phases of the menstrual cycle and estrogen 
levels to naturally differ, some participants were assessed at the same time in their cycle while 
other participants did not uniformly progress through the menstrual cycle. This led to many 
individuals changing treatment group in a non-uniform fashion, thus limiting statistical analyses. 
 In the future, to gain a better understanding of the exact relationship between estrogen 
level fluctuations during the menstrual cycle and changing olfactory abilities, it would be prudent 
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to be able to classify each individual by what stage of the menstrual cycle in which they begin 
the study. Grouping individuals this way would allow for better control and determination of 
when a second assessment should occur.  
Furthermore, both pregnant and non-pregnant women should be assessed a minimum of 
three times.  In the current study, resource and time factors limited the scope to two separate 
assessments. However, in the future measuring olfactory abilities and estrogen levels during each 
trimester and in each phase of women’s menstrual cycle will allow for a more precise 
representation of how hormone levels, hormone type, and olfactory ability fluctuate. 
 
Statistical Analysis 
 With the limited sample of many of the reported demographic selections, the 
relationships described could be due to chance. The demographic and olfactory ability 
relationships reported, while significant at an alpha level of .05, could be viewed in a more 
conservative manner to more accurately assess actual relationships. When looking further into 
possible relationships between demographic data and olfactory ability, focusing on and 
increasing the sample size directionally to include people with specifically highlighted previous 
health histories (e.g., cancer) could be beneficial.  
 
Blood Analysis 
 Analyzing the blood with the HPLC was a good first step in analysis. However, the peak 
areas determined from the HPLC output did vary in both retention time and area when compared 
to the standard solutions. This is most likely due to other small molecules being present and 
detected. Centrifugation only allows for separation up to a certain size molecule. Estrogen is not 
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the smallest molecule in the blood, nor is it the only small molecule present in our blood. In 
addition to other hormones, there are several other possible steroids, proteins and lipids that 
could be present. 
 In the future, blood samples should be analyzed as was done in the current study, but the 
analysis should be lengthened. Due to time and logistic constraints only a single one milliliter 
sample of blood was analyzed from each tube. For the most representative filtrate mixture of a 
person’s blood contents, three one milliliter samples should be drawn, centrifuged, and then 
combined and diluted in preparation for HPLC analysis. Once a retention time has been recorded 
for a sample similar to that of the standard solutions, that sample should be run back through the 
column and the material corresponding to the peak area measurements should be extracted for 
further analysis. This further analysis could include mass spectrometry analysis to assess the 
extracted samples contents by molecular weight. 
 Also, estrogen was the only hormone examined in this study, yet there are many 
hormones that are present and fluctuate in the blood during menstruation and pregnancy. Once a 
procedure for exact analysis has been finalized for estrogen, the project can then be expanded to 
the analysis of blood estrogen levels to that of progesterone, luteinizing hormone, follicle 
stimulating hormone, and even gonadotropin releasing hormone.  
In addition to examining other hormones, extending the scope of research to investigate 
disease, infection, and environmental biomarker relationships to and influence on olfactory 
ability is the next step in this area of research. Biomarkers have been found to be indicative of 
many biological and psychological conditions (Aronson, 2005). In turn, biomarkers could be 
employed from the external environment. If bound to specific odorants, biomarkers could be 
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used as a tracking system, allowing for a better understanding of the specific nuanced differences 
between how odorants travel within the olfactory system. 
 
Measurement of Olfactory Ability 
 In the current study olfactory ability was assessed using objective measurements of 
estimated thresholds, sensitivity, and response bias. While the modified WUTC allows for a 
comprehensive assessment of olfactory sensitivity, it does not assess the totality of olfactory 
ability.  A measure could be included to assess if odor identification changes in conjunction with 
olfactory sensitivity and hormone levels. Participants spent on average from one hour to two 
hours per assessment participating in this research. While adding a lengthy measure of odor 
identification ability would be cumbersome, and even counterproductive, possibly causing 
participant fatigue, adding a relatively short measure like the University of Pennsylvania Smell 
Identification Test (Doty, Shaman, Kimmelman, & Dann, 1984) could be beneficial in yielding a 
more comprehensive look at the changes experienced in the olfactory system.  
 
Nature of This Research 
 This research contributes to the current breadth of knowledge in a profound way. 
Previous research indicates that this is the first of its kind to compare blood hormone levels to 
the olfactory abilities of pregnant women. Much of the current knowledge concerning if and how 
olfaction changes during pregnancy is based in subjective measures of self-report. This has led to 
findings being heterogeneous and inconclusive.  The current study is a first step in the direction 
of an objective understanding of how olfaction might be influenced throughout pregnancy. 
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 Furthermore, beyond studies that have used self-report survey measures as a means of 
assessment, this study is one of the largest to assess the non-pregnant female population’s 
olfactory abilities in conjunction with any measure of hormone fluctuation or stage of the 
menstrual cycle. In addition, the WUTC has allowed for assessment to incorporate and 
investigate four distinct odorants. Previous research involving threshold and sensitivity measures 
has been limited to single odorant specifications. By assessing multiple odorants, the current 
study was able to compare and contrast the possible differences of how each odorant is processed 
within the olfactory system. In turn, this research has allowed for the finding that estrogen 
influences some of the fluctuations in olfaction seen in non-pregnant and pregnant populations. 
The magnitude and depth of this research has been a result of interdisciplinary 
cooperation – a component that has only strengthened the level of inquiry possible. Future 
research should attempt to incorporate multiple disciplines in the discovery, research, and 
refinement of what is known and unknown regarding the chemical senses in humans. 
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APPENDIX A 
CHEMICAL STRUCTURE OF ODORANTS
50 
Vanillin: 
 
Caraway: 
 
Spearmint: 
 
Muscone:  
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APPENDIX B 
DEMOGRAPHIC QUESTIONNAIRE
52 
Demographics Questionnaire 
 
Age (in years): _________ 
Gender (circle one): Male Female 
If female, please also answer the questions located on the last page. *** 
Ethnicity (circle one): Caucasian African American   Asian  Latino 
Bi-Racial Other (please indicate): _______________________________ 
 
Do you currently smoke (circle one):       Yes No 
If yes, how many cigarettes per day?_____  Cigars per day?____ 
What type of cigarettes do you smoke? __________________________ 
How many years have you smoked? ______________ 
Do you currently use other tobacco products? (Circle one):                 Yes No 
If yes, what quantity per day?_______ 
What type of tobacco product do you use? ________________________ 
How many years have you used tobacco? _______________ 
If not currently smoking/using tobacco products, have you ever used either? (Circle one):  Yes No 
If yes, how long ago did you stop?_______ 
How many cigarettes did you smoke per day?_____;  Cigars per day?_____ 
What type of tobacco product did you use? _________________________ 
Did your ability to smell change after you stopped using tobacco? (Circle one): Yes No 
 If yes, how? ____________________________________________ 
 
What is your current occupation: _______________________________________________ 
 
Highest grade completed? (Circle only one number): 
Grade School:      6          7          8          9          10          11          12       
Years of College:      1          2          3          4          5          6+ 
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Please indicate if you have had past history of the following medical illnesses. (Circle Yes or No): 
 
High blood pressure  Yes No  Diabetes   Yes No 
Arthritis   Yes No  Heart disease   Yes No 
Thyroid disorder  Yes No  Chronic Headaches  Yes No 
Lung trouble   Yes No  Gout    Yes No 
Epilepsy   Yes No  Circulation problems  Yes No 
Broken nose   Yes No  Anemia    Yes No 
Strokes    Yes No  Eye disease (e.g. Glaucoma) Yes No 
Asthma    Yes No  Cancer    Yes No 
 
 
Please indicate if you have had past history of the following medical illnesses. (Circle Yes or No): 
 
Hepatitis   Yes No  Ulcer    Yes No 
Hiatal hernia   Yes No  Kidney disease   Yes No 
Sleep Apnea   Yes No  Skin disease   Yes No 
Prostate problems  Yes No  Infections   Yes No 
Bleeding/clotting disorder Yes No  HIV    Yes No 
TB    Yes No  Neurological disease  Yes No 
Food allergies   Yes No  Sinus problems   Yes No 
Medical allergies  Yes No  Deviated septum  Yes No 
Seasonal allergies  Yes No  Concussion/head trauma Yes No  
Specific Allergy(ies): _________________________________________________________________ 
Other medical illness(es): ______________________________________________________________ 
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Please indicate if you are currently taking any of the following types of medications or vitamins. 
(Circle Yes or No): 
Antibiotics   Yes No  Antidepressants   Yes No 
Lithium   Yes No  Antianxiety   Yes No 
Blood Pressure   Yes No  Hormone replacements  Yes No 
Antihistamines   Yes No  Pre-Natal Vitamins/DHA Yes No 
Anti-inflammatory†  Yes No   
†Including ibuprofen 
Antineoplastic††  Yes No 
††Examples of Antineoplastics are Elspar (asparaginase), Alkeran (melphalan), floxuridine, 
lomustine, procarbazine, thioguanine, thiotepa 
Stimulant medications††† Yes No 
†††Examples of Stimulant medications are Adderall and Vyvanse  
 
***Females (optional, but each question is VERY BENEFICIAL to answering research questions) 
If FEMALE: What is the date of the first day of your most recent period? _____________________ 
If FEMALE: What is the date of the last day of your most recent period (use today’s date if you are 
currently menstruating)? _________________________ 
If FEMALE: Are you currently taking birth control? (Circle one):    Yes No 
 If yes, what type (e.g. oral contraception, IED, patch, etc.)? __________________________ 
 If yes, what brand of birth control are you using (e.g. Yaz, Apri, etc.)? _________________ 
 If yes, how long have you been taking birth control? _______________________________ 
If FEMALE: Are you currently pregnant? (Circle one):      Yes No 
 If yes, how many weeks pregnant are you? ________________ 
 If known, what was your conception date? ________________ 
 If known, what is your expected due date? ________________ 
 If known, what sex is your child? _______________________ 
If FEMALE: Have you had a previous pregnancy? (Circle one):    Yes No 
 If yes, how many previous pregnancies have you had? __________________ 
 Of that/those, how many pregnancies resulted in a live birth?____________
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APPENDIX D 
MODIFIED WUTC THRESHOLD TEST INFORMED CONSENT
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INFORMED CONSENT FORM (Threshold Test) 
 
Odor Sensitivity and Hormone Levels 
 
Please read this consent document carefully before you decide to participate in this study. The 
Institutional Review Board of the University of Tennessee at Chattanooga (FWA00004149) has 
approved this research project #13-139. 
 
Purpose of the research study:   
 
The purpose of this study is to measure odor sensitivity in healthy female, pregnant and non-
pregnant, adults. 
 
What you will be asked to do in the study: 
 
You will initially be asked to complete a brief demographics page. A researcher will then begin 
the threshold test by presenting a tube filled with clear liquid beneath your nose for 5 seconds. 
After these 5 seconds have passed, you will be given 10 seconds to tell the researcher “yes” (you 
did detect an odor) or “no” (you did not detect an odor). The test contains 54 tubes with various 
odors and concentrations, although not all of the tubes will contain odors. 
 
Time required: 
 
~ 45 minutes 
 
Risks and Benefits: 
 
You may experience some nasal dryness from prolonged smelling. We do not anticipate any 
direct benefit from the study, but we do appreciate your participation as this will add to a 
growing body of research that will benefit others in the future.  
 
Compensation: 
 
A nontransferable gift card will be issued to you during the second portion of your participation 
in this study. 
 
Confidentiality: 
 
Your identity will be kept confidential to the extent provided by law. Your information will be 
assigned a code number. The list connecting your name to this number will be kept in a locked 
file in my research office to which only I and my other research team members have access. 
When the study is completed and the data have been analyzed, the list will be destroyed. Your 
name will not be used in any report. 
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Voluntary participation: 
 
Your participation in this study is completely voluntary. There is no penalty for not participating. 
 
 
Right to withdraw from the study: 
 
You have the right to withdraw from the study at any time without consequence. 
 
 
Whom to contact if you have questions about the study: 
Carrie LeMay (344 Holt Hall, 423-506-5987 and carrie.lemay@utc.edu) 
William Tewalt (344 Holt Hall, wtewalt@gmail.com) 
Dr. Nicky Ozbek (350 Holt Hall, 425-4285 and Nicky-Ozbek@utc.edu).   
 
 
Agreement: 
 
I have read the procedure described above. I voluntarily agree to participate in the procedure and 
I have received a copy of this description. 
 
Participant Signature: ____________________________________ Date: _________________ 
 
Printed Name: __________________________________________ 
 
 
If you have any questions about your rights as a subject/participant in this research, or if you 
feel you have been placed at risk, you can contact Dr. Bart Weathington, Chair of the 
Institutional Review Board, at 423-425-4289.  Additional contact information is available at 
www.utc.edu/irb  
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INFORMED CONSENT FORM (Blood Donation) 
 
Odor Sensitivity and Hormone Levels 
 
Please read this consent document carefully before you decide to participate in this study. The 
Institutional Review Board of the University of Tennessee at Chattanooga (FWA00004149) has 
approved this research project #13-139. 
 
Purpose of the research study:   
 
The purpose is to determine various hormone levels in the blood samples.  
 
What you will be asked to do in the study: 
 
You will be asked to provide a sample of blood that will be stored for later analysis in the 
determination of hormone levels.  
 
Time required: 
 
~30 minutes 
 
Risks and Benefits: 
 
Donors will be screened for previously diagnosed allergic response to mild volatile chemicals.  
Subjects will be exposed to hypodermic needles.  
 
Compensation: 
 
No direct compensation will be given.  
 
Confidentiality: 
 
Your identity will be kept confidential to the extent provided by law. Your information will be 
assigned a code number. The list connecting your name to this number will be kept in a locked 
file in my office to which only I and my other research team members have access. When the 
study is completed and the data have been analyzed, the list will be destroyed. Your name will 
not be used in any report. 
 
Voluntary participation: 
 
Your participation in this study is completely voluntary. There is no penalty for not participating. 
 
Right to withdraw from the study: 
 
You have the right to withdraw from the study at any time without consequence. 
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Whom to contact if you have questions about the study: 
Carrie LeMay (344 Holt Hall, 423-506-5987 and carrie-lemay@utc.edu) 
 
Dr. Manuel F. Santiago (615 McCallie Avenue, 425-5364 and Manuel-Santiago@utc.edu).   
 
 
Agreement: 
 
I have read the procedure described above. I voluntarily agree to participate in the procedure and 
I have received a copy of this description. 
 
Participant Signature: ____________________________________ Date: _________________ 
 
Printed Name: __________________________________________ 
 
 
If you have any questions about your rights as a subject/participant in this research, or if you 
feel you have been placed at risk, you can contact Dr. Bart Weathington, Chair of the 
Institutional Review Board, at 423-425-4289.  Additional contact information is available at 
www.utc.edu/irb  
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APPENDIX F 
BLOOD ASSURANCE OF CHATTANOOGA INFORMED CONSENT
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  Phlebotomy educational material and consent 
 
Thank you for allowing us to collect your blood today.  We would like to explain the risks of 
donating tubes of blood and allow you to ask any questions.  Donating blood is not risk free.  If 
you do not feel well, then notify an employee.   
 
What are the possible adverse effects of blood donation? 
 
Pain, redness, swelling and bruising and rarely phlebitis, vascular injury, local infection, muscle 
or tissue damage, and scarring. Anxiety, fever, headache, lightheadedness, paleness, sweating, 
chills, nausea, vomiting, dizziness, excessive tiredness, weakness, hyperventilation, itching, 
hives, low blood pressure and fainting.  Fainting or loss of consciousness following donation can 
cause the donor to fall which can lead to physical injuries with long-term complications 
including death.   Other rare and severe symptoms can include seizures, incontinence, chest pain, 
respiratory problems including shortness of breath, difficulty breathing, a severe allergic 
reaction, tetany and cardiac arrhythmia.   
 
What should I do after donating the tubes of blood? 
 
• Eat and drink in the recovery area.  Sit for 15 minutes before leaving. 
• Leave the adhesive bandage around the arm for 1 hour and the Band-Aid on for 4 hours.  
If the needle site bleeds, apply firm pressure over the bandage and raise the arm for 5-10 
minutes.   
• Avoid strenuous activities such as participating in team sports, lifting, pushing or picking 
up heavy objects for 4-5 hours after donating. 
• Apply ice if a bruised area appears on the arm.  The ice should be applied periodically for 
10-15 minutes for the first 24 hours following donation. In subsequent days, periodically 
apply warm moist heat to the area.  The area may be discolored for 10 days or more. 
• If you feel dizzy or lightheaded, do not drive. Sit down and lower the head or lie down, 
keeping the head lower than the rest of the body if you feel dizzy. 
• Call us at 1-800-962-0628 or 423-756-0966 if dizziness persists, or if any other problems 
occur after donation. 
I understand that I am about to have blood drawn from my arm (phlebotomy).   My blood will be 
used for research purposes.  I have been given the opportunity to ask questions and can withdraw 
my consent at any time.  
 
Donor Signature: ____________________________________________ Date:_____________ 
    
 
Print: 
First Name:__________________Print MI _______Last____________________Suffix _____ 
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